Objective: In the present study we analyzed the pattern of pendrin (PDS) and sodium/iodide symporter (NIS) gene expression in some thyroid carcinoma cell lines and a series of thyroid tumoral tissues. Methods: Total RNA was extracted from all cell lines and from 53 tissues, and gene expression was examined by RT-PCR. Semiquantitative`multiplex' RT-PCR was used to assess variations in PDS gene expression among various thyroid pathologies. Pendrin expression was determined in the thyroid cell lines by Western blot analysis. Results: PDS mRNA was expressed in all the cells investigated; conversely, NIS mRNA was detectable only in the B-CPAP cells. Pendrin protein was expressed in B-CPAP and WRO cell lines, reduced in FRO and absent in ARO cells. PDS gene expression was not detected in 5 of 25 differentiated thyroid carcinomas (DTC) while NIS gene was not expressed in six carcinomas. A concordance expression of both PDS and NIS transcripts was found in 20 DTC. In contrast, 2 neoplastic thyroid tissues carrying undetectable PDS mRNA maintained NIS transcript, and 3 thyroid carcinomas negative for NIS mRNA retained the expression of PDS gene. A semiquantitative analysis showed that the mean PDS mRNA levels were signi®cantly decreased in DTC tissues.
Introduction
Highly specialized proteins regulate iodine metabolism and hormonogenesis in thyroid cells. A number of these proteins have already been identi®ed and functionally characterized. This complex machinery appears imbalanced during thyroid neoplastic transformation. Indeed, a variety of iodine metabolism abnormalities have been demonstrated in thyroid cancer tissue (1) . Moreover, a loss of iodide trapping ability appears to be an early feature during oncogenic transformation of thyroid cells in vitro (2) . Recently pendrin, a highly hydrophobic transmembrane protein composed of 780 amino acids, has been recognized as a chloride and iodide transporter (3) , suggesting a potential role in thyroid iodine metabolism. Indeed, the PDS gene, encoding pendrin, is highly expressed in thyroid tissue (4, 5) , although its role in thyroid pathology is not fully clari®ed. However, pendrin is detectable at the apical membrane of the thyrocytes; this localization, as well as its functional activity in vitro, supports its role in iodide transport into the follicular lumen (5, 6) . Mutations of the PDS gene are responsible for Pendred syndrome, an autosomal recessive disease characterized by goiter and congenital deafness (7) . Furthermore, in a previous study we found a variability in PDS gene expression in various thyroid disorders (5) . However, whether pendrin plays a role in the iodine derangement occurring in thyroid carcinoma has yet to be clari®ed. On the other hand, several studies have already demonstrated a loss or decrease of the sodium/iodide symporter (NIS) gene expression in both primary and metastatic differentiated thyroid carcinomas (8±10).
The relative contribution of defective NIS and/or PDS expression in determining the reduced or absent iodineconcentrating ability in thyroid cancer cells remains to be established. In this regard, we analyzed the expression of the PDS gene and pendrin in a number of human thyroid carcinoma cell lines carrying various degrees of malignancy. In addition, we evaluated PDS mRNA levels and compared PDS and NIS gene expression in a series of thyroid tumors, including benign and malignant primary and metastatic carcinomas.
Materials and methods

Cell culture and iodide uptake
The human thyroid cell lines used in this study were B-CPAP (11) (from papillary carcinoma, provided by A Fusco, University of Catanzaro, Italy), WRO (12) (from follicular carcinoma, provided by G Juillard, UCLA, USA), FRO (13) and ARO (12) (both from anaplastic carcinoma, provided by G Juillard). All cell lines except the ARO were grown in Dulbecco's modi®ed Eagle's medium containing 10% fetal bovine serum, penicillin/ streptomycin and amphotericin B. The ARO cell line was grown in RPMI 1640. As positive control, we used normal thyroid cells in continuous culture.
Iodide uptake assay was performed as described previously by Weiss et al. (14) . Each experiment was done at least twice in quadruplicate and the FRTL-5 cells were used as positive controls.
Human thyroid tissues
Forty-one thyroid tumors and twelve normal thyroid tissues collected at the Gustave Roussy Institute (Villejuif, France) and at the University of Catanzaro (Italy) were examined. Tissues obtained at surgery were immediately frozen and stored in liquid nitrogen until analysis. Tumors were histologically classi®ed according to the World Health Organization (WHO) recommendations (15) . The local ethical committee approved this work.
RNA extraction and RT-PCR
Total RNA was extracted from cell lines using the Qiagen RNA/DNA kit (Qiagen S.p.A, Milano, Italy), following the manufacturer's instructions. Total RNA was extracted from frozen fresh tissues using the RNA Btm technique (Bioprobe Systems Richmond, CA, USA), following the manufacturer's instructions as described previously (16) . The tumor tissues used for RNA isolation in this study were microdissected by the pathologist to exclude contamination of surrounding normal thyroid cells.
Complementary DNA (cDNA) was synthesized from 1 mg total RNA according to the manufacturer's instructions (Roche Diagnostics SpA, Monza, Italy), as described previously (17) . The mixture was incubated at 25 8C for 10 min, at 42 8C for 60 min, heated to 99 8C for 5 min, and then stored at 220 8C. PCR ampli®cation was performed using 5 ml cDNA, as described previously (18) . The samples were subjected to 40 cycles of ampli®cation and PCR conditions for the PDS gene were as follows: denaturation at 94 8C for 1 min, annealing at 57 8C for 1 min and extension at 72 8C for 1 min. Ten of 50 ml of the ampli®cation products were then run on 1.5% Tris±borate±EDTA agarose gel containing ethidium bromide and were analyzed to con®rm a positive or negative outcome.
Primer (4) . The PDS primers spanned exon±intron junctions of the gene to exclude genomic DNA contamination. For the thyroglobulin (Tg), thyroperoxidase (TPO) and NIS gene ampli®cation, we used the primer oligonucleotides previously described (17, 18) . All primers were from Life Technologies S.r.l., San Giuliano Milanese (MI), Italy.
Multiplex semiquantitative RT-PCR
In human thyroid tumors, a semiquantitative`multiplex' RT-PCR in the same tube was designed to compare the RT-PCR products of the PDS gene with b-actin gene products to determine the relative expression levels of these genes.
The PCR ampli®cation was performed using 5 ml cDNA as described previously and the samples were subjected to 32 cycles of ampli®cation. The PCR conditions were as follows: denaturation at 94 8C for 1 min, annealing at 62 8C for 1 min and extension at 72 8C for 1 min.
Primer oligonucleotides for the PDS gene (PDS1S-1A) were: 5 H primer, 5 H -AGCAGAGACAGGTCATGGCA-3 H and 3 H primer, 5 H -ATCCGACAGGAACTGCAGCT-3 H . The ampli®cation yielded a 357 base pair DNA product corresponding to fragment 211±567 according to the sequence of the PDS cDNA reported in the GeneBank (4). Primer oligonucleotides for the b-actin gene were: 5
The ampli®cation yielded a 482 base pair DNA product corresponding to fragment 209±691 according to the published sequence of the b-actin gene (19) .
The PDS and b-actin primers spanned exon±intron junctions of the gene to exclude genomic DNA contamination. The reaction conditions were optimized to ensure that the ampli®cation for both PDS and b-actin remained within the exponential range, by assessing the variation in signal intensity for PDS and b-actin at various cycle numbers. Three different ratios of primers were tested to get the same ef®ciency of ampli®cation, and the ratio 1:1 was used (data not shown).
Ten of 50 ml of the ampli®cation products were run on 1.5% Tris±borate±EDTA agarose gel containing ethidium bromide. The bands of the positive ®lm were scanned and the density and the width of each PCR product was measured using the NIH Image Program (Wayne Rasband, National Institutes of Health, USA).
Western blot analysis
Total proteins were extracted from thyroid cell lines as follows. Con¯uent cells from 3 Petri dishes were collected and homogenized in 1 ml buffer containing 250 mmol/l sucrose, 10 mmol/l HEPES-KOH (pH 7.5), 1 mmol/l EDTA, 1 mmol/l phenylmethylsulfonyl¯uor-ide, 10 mg/ml leupeptin, 10 mg/ml aprotinin. The homogenate was centrifuged at 14 000 g (4 8C for 15 min) and the supernatant (which contained the whole cell lysate) was quanti®ed spectrophotometrically using the Bradford method (20) .
Thirty micrograms proteins were loaded on a 4±20% gradient SDS-polyacrylamide gel and subjected to electrophoresis at a constant voltage (110 V). Electroblotting to a Hybond ECL-PVDF nitrocellulose membrane (Amersham S.r.l., Milano, Italy) was performed for 2 h at 125 mAmp using a Mini Trans blot electroblotting system (Bio-rad Laboratories S.r.l, Milano, Italy). Blocking was done using TTBS/milk (1% Tween 20, TBS (20 mmol/l Tris-HCl, 150 mmol/l NaCl; pH 7.5), and 5% non fat dry milk) for 2 h at room temperature. The membrane was then incubated with a 1/1500 dilution of af®nity-puri®ed rabbit antipendrin polyclonal antibody (5) or a 1/5000 dilution of mouse monoclonal anti-human b-actin antibody, overnight at 4 8C in TTBS/milk. After one 15-min and two 5-min washes in TTBS, the membrane was incubated with a 1/2000 dilution of a horseradish peroxidase conjugated anti-rabbit or anti-mouse antibody in TTBS/milk. After one 15-min and two 5-min washes in TTBS, the protein was visualized by an enhanced chemiluminescence Western blot detection system (ECLplus, Amersham S.r.l.).
Statistical methods
The expression of PDS transcripts detected in the different histotypes was compared with that in normal thyroid tissues. The signi®cance of differences between group means was analyzed by Student's (unpaired) t-test. A level of P , 0X05 was considered statistically signi®cant.
Results
Iodide transporters expression in human thyroid carcinoma cell lines
None of the thyroid carcinoma cell lines used in this study, comprising a spectrum ranging from well differentiated to undifferentiated phenotypes (11±13), was able to concentrate iodine (Table 1) . To examine whether the expression of the two molecules known to act in vitro as iodide transporters are altered in these cell lines, an RT-PCR analysis was performed. Figure 1 shows detectable levels of PDS transcript in all cell lines; conversely, the expression of the NIS mRNA was detected only in the B-CPAP cell line. To assess whether the PDS transcript detected in all cells was truly translated into the native protein, a Western blot analysis using a speci®c antibody directed against pendrin was performed. As shown in Fig. 2, a band of approximately 95 kDa corresponding to pendrin 
Pendrin mRNA expression in human thyroid tumor tissues
The pattern of expression of both PDS and NIS genes was also explored in a series of normal and tumoral thyroid samples. All tissues investigated displayed the Tg and TPO transcripts (data not shown), indicating therefore the integrity of the mRNA and the cDNA obtained from tissue specimens. PDS mRNA was detected in all normal thyroid tissues as well as in toxic adenomas and follicular thyroid carcinomas, even though it was at different expression levels. On the other hand, PDS gene expression was not detected in 5 of 19 papillary carcinomas (nos 6, 7, 11, 14 and 17) and in 1 of 11 hypofunctioning thyroid adenomas (no. 31) ( Table 2) .
Three of ®ve human thyroid carcinomas negative for the PDS gene expression were also negative for NIS transcripts (nos 6, 11 and 14). Conversely, 2 carcinomas negative for PDS mRNA maintained the expression of NIS gene (nos 7 and 17). Moreover, 3 carcinomas negative for NIS mRNA maintained the expression of PDS gene (nos 4, 15 and 20) ( Table 2 ). Expression of PDS gene was also investigated in the metastatic tissues from two patients (nos 17 and 18) ( Table 2 ). In both cases we found the same behavior as in the corresponding primary carcinomas (negative for PDS and positive for NIS in no. 17; positive for both PDS and NIS in no. 18) (data not shown).
A semiquantitative RT-PCR assay was used to analyze PDS mRNA levels. Mean levels were expressed relative to the b-actin mRNA, used as internal control (Fig. 3) . The PDS mRNA levels were variable among normal thyroid tissues as well as in tumoral thyroid tissues. The mean PDS mRNA levels were signi®cantly lower in papillary and follicular thyroid carcinomas than in normal thyroid tissues P , 0X001 (Fig. 4) . Among carcinomas, mean levels of expression were signi®cantly lower in follicular carcinomas than in papillary carcinomas P , 0X005 (Fig. 4) . Also, PDS gene expression was lower in hypofunctioning thyroid adenomas than in normal thyroid tissues P , 0X001 (Fig. 4) . A slight, but not signi®cant decrease in PDS gene expression was observed in toxic adenomas (Fig. 4) . In the light of a possible clinical signi®cance of our ®ndings, we examined primary thyroid cancer specimens obtained from a group of Tg-positive and Tgnegative post-therapeutic radioiodine whole body scan (WBS) patients (nos 6, 11, 14, 16, 17, 18, 20 and 21, Table 2 ). The majority (5 out of 8) of the samples did not express one or both of the two genes studied. More interestingly, in one case (no. 17, Table 2 ) the metastatic tissue negative at the post therapeutic WBS was also investigated, and neither the metastasis nor the primary tumors expressed the PDS gene, while the NIS transcript was fully detected. Furthermore, PDS gene expression, when present, was markedly reduced (data not shown).
Discussion
The molecular mechanisms underlying the reduction/ loss of ability to concentrate iodide in human thyroid tumors are not completely understood. Two proteins capable of transporting iodide in vitro, NIS and pendrin, have recently been identi®ed and their genes have been cloned. These proteins are expressed in the thyroid gland as well as in several other tissues (4, 9) . However, it is not completely clear how pendrin displays its iodide transporter function in thyroid cells. In both benign and malignant human thyroid tumors, several studies have demonstrated a decrease or a loss of the NIS mRNA and protein expression (17, 21±25) in the absence of abnormalities of the structural gene (26). Nevertheless, some thyroid tumors maintain NIS expression despite the loss of iodide concentrating ability, suggesting that additional alterations may be involved. However, the relative contribution which alterations to NIS and/or pendrin make to the defective iodine metabolism of neoplastic thyroid tissue is unclear.
In the present study, ®rst, we examined the expression of NIS and pendrin in some human thyroid carcinoma cell lines carrying a varying degree of malignancy (11±13). We previously demonstrated that oncogene-transformed thyroid cell lines show a reduction or absence of NIS gene expression (2) . Similarly, NIS mRNA was not detectable in any of the human cell lines examined except the B-CPAP cell line in which its expression was very low. Accordingly, no iodide uptake was found in these human cell lines. In contrast, messenger RNA for PDS was expressed in all the cell lines investigated. Moreover, Western blot analysis showed different levels of expression of pendrin in the various cell lines, with the more differentiated ones (B-CPAP and WRO) presenting the higher amounts, and the less differentiated cells showing remarkably reduced (FRO) or absent (ARO) pendrin expression levels. These data, therefore, suggest that different alterations, also related to the more or less aggressive phenotype, may affect PDS and NIS gene expression and suggest a key role in vitro of NIS rather than of pendrin in the iodide uptake by neoplastic thyroid cells.
Next, by examining primary thyroid carcinomas, PDS gene expression was not detected in 5 of 19 papillary carcinomas. However, the absence of PDS transcript was not restricted to the malignant phenotype, being also found in one hypofunctioning benign follicular adenoma. Furthermore, a semiquantitative analysis of the PDS gene expression showed that the mean PDS mRNA levels were signi®cantly decreased in human thyroid carcinomas and the mean levels of the PDS transcript were signi®cantly lower in follicular carcinomas than in papillary thyroid carcinomas. Unfortunately, the absence of suf®cient amount of tissue meant that the study of the protein expression in this series of thyroid tumors was not possible.
In addition, when we compared PDS and NIS transcripts in the 25 differentiated thyroid carcinomas, a concordant expression of both genes was found in 17 samples. This is in agreement with our previous data in which a positive relationship was found between PDS and NIS gene expression in another series of differentiated thyroid carcinomas (5, 23) . Indeed, lack of expression of both PDS and NIS genes was found in Figure 4 PDS mRNA levels in different human thyroid tissues. The bars represent the mean^S.D. PDS mRNA levels in the thyroid tissues examined (the same as in Table 1 except the negative samples). Levels of PDS gene are expressed relative to b-actin mRNA as described in Materials and methods. Bar 1 n 12Y normal thyroid tissues; bar 2 n 14Y papillary thyroid carcinomas; bar 3 n 6Y follicular thyroid carcinomas; bar 4 n 10Y cold thyroid adenomas; bar 5 n 5Y toxic adenomas.
three thyroid carcinoma samples. In contrast, it is noteworthy that two papillary thyroid tumors showing undetectable PDS mRNA levels, maintained NIS gene expression. Conversely, three thyroid tumors negative for NIS mRNA transcript retained the expression of PDS gene.
Although the molecular mechanisms of these alterations are not known, our data show a differential expression pattern of the PDS and NIS genes in human thyroid cancers. On the other hand, the two gene products, at least in thyroid cells, display a distinct localization, NIS and pendrin being localized in the basolateral membrane and in the apical border of thyrocyte respectively. This probably re¯ects their distinct function, NIS being primarily involved in thyroidal iodide uptake from the blood, whereas pendrin mainly acts to deliver intracellular iodide into the follicular lumen.
Furthermore, PDS gene expression was reduced in this group of thyroid carcinomas. The relevance of this observation has yet to be established, but it suggests the possibility that, even though the iodide symporter is active, the impairment of the organi®cation system (pendrin or even TPO molecules) may result also in a decreased ability to concentrate iodide. Indeed, alterations of the pendrin expression by compromising the ef®ciency of the iodide organi®cation process may decrease the intrathyroidal iodide retention. This could affect, therefore, the ef®cacy of radioiodine treatment of thyroid carcinoma metastases. In conclusion, a variety of abnormalities in iodine metabolism, including alterations in pendrin expression, may contribute to the loss or reduction of the radioiodine concentrating ability by thyroid cancer tissue. 
